We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
- Authors
Hong, A. R.; Kim, J.; Lee, K.; Kim, T.; Im, S.; Moon, H.; Han, W. S.; Noh, D.; Kim, S.; Shin, C.
- Abstract
Summary: In non-osteoporotic postmenopausal women with breast cancer, aromatase inhibitors (AIs) negatively affected bone mineral density (BMD), lumbar spine trabecular bone score (TBS) as a bone microarchitecture index, and hip geometry as a bone macroarchitecture index. Introduction: AIs increase the risk of fracture in patients with breast cancer. Therefore, we aimed to evaluate the long-term skeletal effects of AIs in postmenopausal women with primary breast cancer. Methods: We performed a retrospective longitudinal observational study in non-osteoporotic patients with breast cancer who were treated with AIs for ≥3 years (T-score >−2.5). Patients with previous anti-osteoporosis treatment or those who were given bisphosphonate during AI treatment were excluded from the analysis. We serially assessed BMD, lumbar spine TBS, and hip geometry using dual-energy X-ray absorptiometry. Results: BMD significantly decreased from baseline to 5 years at the lumbar spine (−6.15%), femur neck (−7.12%), and total hip (−6.35%). Lumbar spine TBS also significantly decreased from baseline to 5 years (−2.12%); this change remained significant after adjusting for lumbar spine BMD. The annual loss of lumbar spine BMD and TBS slowed after 3 and 1 year of treatment, respectively, although there was a relatively constant loss of BMD at the femur neck and total hip for up to 4 years. The cross-sectional area, cross-sectional moment of inertia, minimal neck width, femur strength index, and section modulus significantly decreased, although the buckling ratio increased over the treatment period (all P < 0.001); these changes were independent of total hip BMD. Conclusions: Long-term adjuvant AI treatment negatively influenced bone quality in addition to BMD in patients with breast cancer. This study suggests that early monitoring and management are needed in non-osteoporotic patients with breast cancer who are starting AIs.
- Subjects
AROMATASE inhibitors; BONES; BREAST tumors; FEMUR; FEMUR neck; BONE fractures; LONGITUDINAL method; LUMBAR vertebrae; OSTEOPOROSIS; PROBABILITY theory; TIME; BONE density; RETROSPECTIVE studies; POSTMENOPAUSE; DESCRIPTIVE statistics; PHOTON absorptiometry; CANCELLOUS bone; THERAPEUTICS
- Publication
Osteoporosis International, 2017, Vol 28, Issue 4, p1413
- ISSN
0937-941X
- Publication type
Article
- DOI
10.1007/s00198-016-3899-6